Sonnet BioTherapeutics Holdings, Inc.
已退市CIK 1106838fmd_1WTW4RTA59ZTBD7EWH7XKYX34Y制造业 · 医药制剂模板: 标准
覆盖范围: 2009年10月01日 至 2025年9月30日，共 62 个期间
| 项目 | FY2018 | FY2019 | FY2019 | FY2020 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| 营业总收入 | 41 | 31 | – | 30 | – | 0 | 0 | 0 | 0 | 1 |
| 净利息收入 | – | – | (0) | – | 0 | – | – | – | – | – |
| 佣金及手续费 | – | – | – | – | – | – | – | – | – | – |
| 已实现投资收益（损失） | – | – | – | – | – | – | – | – | – | – |
| 研发费用 | – | – | 2 | – | 10 | 17 | 21 | 12 | 6 | 8 |
| 营业费用合计 | 23 | 18 | – | – | 24 | 26 | 30 | 19 | 12 | 17 |
| 薪酬与福利 | – | – | – | – | – | – | – | – | 1 | 2 |
| 营业利润 | (5) | (5) | – | – | (24) | (25) | (30) | (19) | (12) | (16) |
| 利息费用 | 3 | 3 | – | 1 | – | – | – | – | – | – |
| 利息及投资收益 | 0 | (0) | – | – | – | – | – | – | – | – |
| 其他营业外收入（支出） | (3) | (3) | – | (1) | – | – | – | – | – | – |
| 税前利润 | (8) | (8) | – | (17) | – | – | – | – | (7) | (16) |
| 所得税费用 | (1) | (1) | – | 0 | – | – | – | – | – | 0 |
| 持续经营净利润 | (7) | (7) | – | (17) | – | – | – | – | – | (16) |
| 净利润 | (7) | (7) | – | – | (24) | (25) | (30) | (19) | (7) | (16) |
| 归属于普通股股东的净利润 | (7) | (7) | – | – | (66) | (25) | – | – | (7) | (16) |